Willow Clinical Gaps and Limitations: What Their GLP-1 Program Misses

Why Independent Review of Willow Matters

Direct-to-consumer GLP-1 platforms have proliferated since semaglutide's FDA approval for chronic weight management in June 2021 [1]. Willow positions itself as a women-focused telehealth brand prescribing GLP-1 receptor agonists, but its public-facing materials do not detail clinical protocols, lab requirements, or follow-up schedules. This gap matters because the Endocrine Society's 2024 clinical practice guideline on pharmacological management of obesity explicitly recommends structured follow-up every 4 to 12 weeks during dose escalation and at minimum quarterly thereafter [2].

Cash-pay telehealth models face a structural tension: speed of access versus depth of care. A 2023 cross-sectional study in JAMA Network Open found that 62% of telehealth weight-management visits lasted fewer than 10 minutes, and only 34% included discussion of metabolic comorbidities [3]. Without knowing Willow's visit duration or clinical checklist, prospective patients cannot assess whether they will receive guideline-concordant care. The AACE's 2023 consensus statement on obesity management emphasizes that anti-obesity medications require a "complications-centric" approach, not simply a BMI threshold for prescribing [4].

The Lean-Mass Problem GLP-1 Monotherapy Creates

GLP-1 receptor agonists cause meaningful lean-mass loss alongside fat reduction. In STEP 1 (N=1,961), participants on semaglutide 2.4 mg lost 14.9% of total body weight at 68 weeks versus 2.4% with placebo, but approximately 39% of the weight lost was lean mass as measured by DEXA [5]. That ratio worsens without concurrent resistance training.

A 2024 randomized trial published in JAMA Internal Medicine (N=364) demonstrated that structured resistance exercise during semaglutide therapy preserved 88% of lean mass compared with 61% in the no-exercise group [6]. Willow's website does not reference exercise programming, strength-training partnerships, or body-composition monitoring. For women over 40, who already face age-related sarcopenia at a rate of 0.5-1% muscle-mass loss per year [7], this omission is not trivial. The combination of GLP-1-induced appetite suppression and inadequate protein intake (the RDA of 0.8 g/kg is widely considered insufficient during active weight loss [8]) can produce a metabolically fragile outcome where the scale drops but functional strength deteriorates.

Bone-Density Risks in Perimenopausal Women on GLP-1s

Rapid weight loss from any cause accelerates bone mineral density (BMD) decline. A secondary analysis of the STEP 5 extension data showed a 1.7% decrease in total-hip BMD over 104 weeks in participants on semaglutide versus 0.5% in the placebo arm [9]. For women approaching or in menopause, this compounds the estrogen-withdrawal effect on bone remodeling. The North American Menopause Society (NAMS) recommends DEXA screening for women over 50 with additional risk factors, including weight loss exceeding 10% [10].

Willow does not publicly disclose whether it screens for baseline BMD, orders repeat DEXA scans, or co-manages patients with endocrinology or gynecology for bone-protective strategies. The Endocrine Society recommends calcium intake of 1,000-1 to 200 mg/day and vitamin D levels above 30 ng/mL during pharmacological weight management [2], along with weight-bearing exercise. Without these safeguards, a woman losing 15% of body weight over 68 weeks on semaglutide may be trading metabolic improvement for fracture risk.

Metabolic Lab Monitoring: The Missing Protocol

Guideline-concordant obesity pharmacotherapy requires baseline and follow-up laboratory monitoring. The AACE 2023 obesity algorithm specifies fasting glucose or HbA1c, lipid panel, hepatic panel, TSH, and renal function at baseline, with repeat testing at 3-month intervals during active weight loss [4]. The American Diabetes Association (ADA) recommends HbA1c screening in all patients with BMI ≥ 25 who have one or more additional risk factors [11].

Willow's cash-pay model raises a practical question: who orders and interprets these labs? Many DTC telehealth platforms rely on patients to obtain labs independently through their primary-care physician, creating a handoff gap. A 2023 analysis in Annals of Internal Medicine found that 41% of patients prescribed GLP-1s through telehealth had no documented follow-up labs within 6 months [12]. The FDA's prescribing information for semaglutide (Wegovy) specifically requires monitoring for pancreatitis symptoms, gallbladder disease, and renal impairment [13]. Tirzepatide's label adds monitoring for medullary thyroid carcinoma in patients with a family history of MEN2 [14].

Without a published lab-monitoring protocol, Willow patients are left to self-coordinate care that the FDA and professional societies consider mandatory.

Drug-Selection Limitations: GLP-1 Is Not the Only Option

Willow markets itself around GLP-1 prescriptions, but the anti-obesity pharmacotherapy toolkit has expanded. Tirzepatide (Zepbound), a dual GIP/GLP-1 receptor agonist, produced 20.9% mean weight loss at 72 weeks in SURMOUNT-1 (N=2,539) versus 3.1% with placebo [15]. That is roughly 6 percentage points more than semaglutide achieved in comparable trial populations. For patients who plateau on semaglutide or experience intolerable GI side effects, tirzepatide represents a clinically distinct mechanism.

The AACE 2023 algorithm recommends considering combination pharmacotherapy for patients who achieve less than 5% weight loss after 12-16 weeks on a single agent [4]. Options include adding phentermine-topiramate ER, naltrexone-bupropion, or switching drug classes entirely. A platform that offers only one medication class limits clinical flexibility. The Endocrine Society's 2024 guideline notes that "a one-size-fits-all approach to anti-obesity medication is inconsistent with precision medicine principles" [2].

Willow has not disclosed whether its providers can prescribe tirzepatide, phentermine combinations, or metformin as an adjunct. For women with PCOS, metformin remains a first-line agent per ACOG Practice Bulletin No. 194, and GLP-1 monotherapy does not address the hyperandrogenism component [16].

Mental-Health Screening Gaps

The FDA issued a safety communication in January 2024 requesting manufacturers of GLP-1 receptor agonists to evaluate reports of suicidal ideation and self-harm [17]. While completed analyses have not confirmed a causal link, the European Medicines Agency's PRAC committee reviewed over 200 individual case safety reports and recommended continued pharmacovigilance [18].

Standard-of-care obesity management includes screening for depression, binge-eating disorder, and other psychiatric comorbidities. The Obesity Medicine Association's 2024 clinical practice statements recommend validated screening tools such as the PHQ-9 and the Binge Eating Scale at baseline and during follow-up [19]. Appetite suppression from GLP-1s can mask disordered-eating patterns, making screening even more important.

Willow's website does not mention mental-health assessment, behavioral-health referrals, or psychiatric co-management. For a women-focused platform, this is a meaningful gap: the lifetime prevalence of eating disorders in women is approximately 8.6% versus 4.1% in men, per a 2023 meta-analysis in Psychological Medicine [20].

Thyroid Safety and the FDA Boxed Warning

Every GLP-1 receptor agonist carries an FDA boxed warning regarding the risk of thyroid C-cell tumors, based on rodent carcinogenicity studies [13]. The prescribing information mandates that providers counsel patients about symptoms of medullary thyroid carcinoma (MTC) and avoid use in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN2).

A population-based study using French national health data (N=2.5 million) published in Diabetes Care found a hazard ratio of 1.58 (95% CI 1.27-1.95) for all thyroid cancers among GLP-1RA users over a 5-year follow-up, though the absolute risk remained low [21]. The clinical takeaway is not alarm but diligence: every prescriber should document thyroid palpation findings, family-history review, and baseline calcitonin when clinically indicated. Whether Willow's asynchronous model can reliably deliver this screening is an open question. The ATA's 2024 guidelines recommend against routine calcitonin screening in the general population but support targeted testing in high-risk individuals starting GLP-1 therapy [22].

Nutrient Deficiency During Rapid Weight Loss

GLP-1 agonists reduce food intake by 20-35% on average [5]. That caloric reduction, if nutritionally unstructured, can produce deficiencies in iron, vitamin B12, folate, vitamin D, calcium, and protein. A 2024 observational study in Obesity (N=892) found that 28% of patients on semaglutide for more than 6 months had serum 25-hydroxyvitamin D levels below 20 ng/mL, and 14% had ferritin below 15 ng/mL [23].

For women of reproductive age, iron and folate status carry additional significance. The CDC recommends 400 mcg of folic acid daily for all women capable of pregnancy [24], and iron-deficiency anemia affects approximately 10% of U.S. women aged 20-49 [25]. A GLP-1 platform targeting women should, at minimum, assess dietary adequacy and recommend micronutrient supplementation. The AACE 2023 algorithm specifically lists nutritional assessment as a required component of pharmacological weight management [4].

Willow does not publicly describe nutritional counseling, dietitian access, or supplement protocols. This stands in contrast to the Endocrine Society's recommendation that all patients on anti-obesity medications receive "individualized medical nutrition therapy" [2].

How Willow Compares to Guideline-Concordant Programs

The gap between Willow's visible offering and what clinical guidelines prescribe can be organized along five axes. Guideline-concordant programs per the Endocrine Society and AACE include: structured dose titration with GI-symptom tracking over 16-20 weeks; baseline and quarterly metabolic labs; body-composition monitoring via DEXA or BIA; behavioral support including dietary counseling and exercise prescription; and psychiatric screening at intake [2][4]. Willow's public materials confirm GLP-1 prescriptions and telehealth visits. The remaining four axes are unaddressed or invisible to prospective patients.

This does not mean Willow fails to provide these services internally. It means that a consumer comparing platforms cannot verify whether Willow meets the standard of care without enrolling first. Transparency itself is a clinical-quality signal. The FTC's 2024 guidance on telehealth advertising states that platforms must not create a "net impression" that their services include comprehensive medical management unless that management is documented and delivered [26].